Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation containing 960mg aripiprazole provided in a single-chamber prefilled syringe that does […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!